A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis
Trial · NCT01050998
Results by group939
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 939
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Who Achieved Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Response at Day 85 | Placebo | 32.6 | percentage of participants | ||
| Percentage of Participants Who Achieved Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Response at Day 85 | Mavrilimumab 10 mg | 37.5 | percentage of participants | ||
| Percentage of Participants Who Achieved Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Response at Day 85 | Mavrilimumab 30 mg | 63.3 | percentage of participants | ||
| Percentage of Participants Who Achieved Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Response at Day 85 | Mavrilimumab 50 mg | 47.9 | percentage of participants | ||
| Percentage of Participants Who Achieved Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Response at Day 85 | Mavrilimumab 100 mg | 68.1 | percentage of participants | ||
| Percentage of Participants Who Achieved Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Response at Day 85 by Region | Placebo | European Region (n=75, 39, 41, 39, 39) | 34.7 | percentage of participants | |
| Percentage of Participants Who Achieved Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Response at Day 85 by Region | Mavrilimumab 10 mg | European Region (n=75, 39, 41, 39, 39) | 41.0 | percentage of participants | |
| Percentage of Participants Who Achieved Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Response at Day 85 by Region | Mavrilimumab 30 mg | European Region (n=75, 39, 41, 39, 39) | 61.0 | percentage of participants | |
| Percentage of Participants Who Achieved Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Response at Day 85 by Region | Mavrilimumab 50 mg | European Region (n=75, 39, 41, 39, 39) | 51.3 | percentage of participants | |
| Percentage of Participants Who Achieved Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Response at Day 85 by Region | Mavrilimumab 100 mg | European Region (n=75, 39, 41, 39, 39) | 66.7 | percentage of participants | |
| Percentage of Participants Who Achieved Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Response at Day 85 by Region | Placebo | Japanese Region (n=17, 9, 8, 9, 8) | 23.5 | percentage of participants | |
| Percentage of Participants Who Achieved Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Response at Day 85 by Region | Mavrilimumab 10 mg | Japanese Region (n=17, 9, 8, 9, 8) | 22.2 | percentage of participants | |
| Percentage of Participants Who Achieved Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Response at Day 85 by Region | Mavrilimumab 30 mg | Japanese Region (n=17, 9, 8, 9, 8) | 75.0 | percentage of participants | |
| Percentage of Participants Who Achieved Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Response at Day 85 by Region | Mavrilimumab 50 mg | Japanese Region (n=17, 9, 8, 9, 8) | 33.3 | percentage of participants | |
| Percentage of Participants Who Achieved Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Response at Day 85 by Region | Mavrilimumab 100 mg | Japanese Region (n=17, 9, 8, 9, 8) | 75.0 | percentage of participants | |
| Percentage of Participants Who Achieved Disease Activity Score of 28 Joints Using Erythrocyte Sedimentation Rate (DAS28 [ESR]) at Day 85 | Placebo | 37.0 | percentage of participants | ||
| Percentage of Participants Who Achieved Disease Activity Score of 28 Joints Using Erythrocyte Sedimentation Rate (DAS28 [ESR]) at Day 85 | Mavrilimumab 10 mg | 50.0 | percentage of participants | ||
| Percentage of Participants Who Achieved Disease Activity Score of 28 Joints Using Erythrocyte Sedimentation Rate (DAS28 [ESR]) at Day 85 | Mavrilimumab 30 mg | 61.2 | percentage of participants | ||
| Percentage of Participants Who Achieved Disease Activity Score of 28 Joints Using Erythrocyte Sedimentation Rate (DAS28 [ESR]) at Day 85 | Mavrilimumab 50 mg | 58.3 | percentage of participants | ||
| Percentage of Participants Who Achieved Disease Activity Score of 28 Joints Using Erythrocyte Sedimentation Rate (DAS28 [ESR]) at Day 85 | Mavrilimumab 100 mg | 66.0 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01050998/results